Advertisement

Volume 134, Issue 4

 

 

July 25, 2019 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: NETosis and TNF in the pathogenesis of deficiency of adenosine deaminase 2. See the article by Carmona-Rivera et al.

Targeting glycogen synthase kinase 3 for therapeutic benefit in lymphoma
Using glycogen synthase kinase 3 (GSK3) inhibitors as well as CRISPR/CAS9-mediated knockout of GSK3a and GSK3b, Wu et al demonstrate that GSK3 is important for lymphoma cell growth and proliferation, suggesting that GSK3 inhibitors offer a pathway for therapeutic targeting in lymphoma.


Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies
Liu and colleagues demonstrate that gait speed is an excellent predictor of unplanned hospitalization, emergency department use, and mortality in patients at least 75 years of age who have a hematologic malignancy.


Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2
Deficiency of adenosine deaminase 2 (DADA2) is a rare disorder leading to variably penetrant systemic vasculitis and stroke. Carmona-Rivera et al demonstrate that increases in extracellular adenosine in this disorder trigger neutrophil extracellular trap (NET) formation, contributing to the inflammatory diathesis.


Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II
Jones et al demonstrate that leukemic stem cells are exceptionally reliant on exogenous cysteine to sustain energy metabolism and that cysteine depletion impairs electron transport. This suggests that cysteine depletion may offer a targeted therapy against acute myeloid leukemia.


How I treat polycythemia vera
Using a series of illustrative cases, Spivak presents his approach to the diagnosis and management of polycythemia vera.


Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy
Zucca and colleagues report that adding lenalidomide to rituximab improves complete response and progression-free survival in previously untreated follicular lymphoma.

View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.